Odyssey Therapeutics, Inc. IPO - What You Need to Know

Thinking about the Odyssey Therapeutics IPO? Biotech investing is exciting but complex. Here is a simple breakdown to help you decide if this is right for you.

1. What does this company do?

Odyssey is a "drug discovery engine." They focus on fixing immune system issues to treat inflammatory and autoimmune diseases. Traditional drugs often suppress the entire immune system, which can be dangerous. Instead, Odyssey uses a mix of high-tech chemistry and AI to build "precision" medicines. These drugs target specific proteins—like SLC15A4 or LRRK2—to treat conditions like lupus or Crohn’s disease without weakening the rest of the patient's immune system.

2. What are their "star" projects?

They have a growing list of projects:

• OD-001: This is their lead program. It targets the SLC15A4 protein. They will use IPO funds to run clinical trials to see if it helps patients with ulcerative colitis.
• The Pipeline: They are working on over 10 other projects in various stages of development, including treatments for Parkinson’s disease and various cancers.

3. How do they make money?

They don't. Odyssey is currently in the research phase. They have no products for sale and have never made a profit. They operate like a high-tech lab, spending cash to develop potential cures. As of March 31, 2026, they had about $175.7 million in cash. Since 2021, they have raised over $726 million from private investors to fund their work.

4. What will they do with the IPO money?

They are listing on the Nasdaq (ticker: ODTX) to keep the lights on through at least 2027. They plan to spend the money as follows:

• $150 million: To fund clinical trials for OD-001.
• $80 million: To move their other programs through early-stage testing.
• Remaining funds: To grow their AI-discovery platform and cover general business costs.

5. What are the main risks?

Biotech is high-risk. Here is the reality:

• The "All or Nothing" Risk: Clinical trials often fail. If OD-001 fails, the company’s value could drop significantly because so much of their worth is tied to this one project.
• Cash Burn: They lost about $145 million in 2025. They will need more cash later, which means they will likely issue more shares. This reduces your ownership percentage.
• Less Disclosure: As an "Emerging Growth Company," they don't have to follow all the reporting rules that larger companies do.
• Internal Controls: They recently found a "material weakness" in their accounting department. They are fixing this by hiring new staff and updating their systems, but poor financial oversight can lead to errors.

6. Who is running the company?

Dr. Gary Glick leads the team. He is a veteran "drug hunter" who previously founded successful companies like IFM Therapeutics. While his team has a strong track record, past success does not guarantee that Odyssey will succeed.

Is this right for you?

Investing in biotech IPOs is like venture capital, not buying a stable stock. Before you decide, ask yourself:

• Can I handle the volatility? The stock price will likely swing wildly based on news about their clinical trials.
• Am I playing the long game? It will be years before they have a product that could potentially generate revenue.
• Is this money I can afford to lose? Never invest money you need for rent, bills, or emergencies into a high-risk company like this.

If you are still interested, the best next step is to read the official S-1 Prospectus on the SEC website. It contains the fine print that every investor needs to see before putting their money on the line.

Disclaimer: I am an AI, not a financial advisor. This guide is for information only. Always read the official prospectus on the SEC website before investing.